News
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring consumer safety.
Swipe to discover more
-
bioMérieux – 2024 Financial Results
Consolidated sales amounted to €3,980 million in 2024, up 10.3% like-for-like from €3,675 million in the prior year period. Reported growth stood at +8.3% for the period. -
Lab Innovations Empower Clinicians in the Fight Against Antimicrobial Resistance
In recent years, antimicrobial resistance (AMR) has sprung to the forefront of many medical and political conversations, with the warning that the prevalence of resistant pathogens could lead to a public health crisis. Ranked a top 10 global public health threat by the World Health Organization, it is estimated that 1.27 million deaths occurred in a single year attributable to AMR. -
bioMérieux and Vall d'Hebron Join Forces Against Infectious Diseases
bioMérieux announces a new strategic research partnership with Vall d'Hebron, one of Spain's largest and most prestigious healthcare institutions. This collaboration aims to advance research and development in the areas of infectious diseases, data surveillance, and laboratory automation.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19